Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 961-970.e11 , December 2009

Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: A meta-analysis of individual patient data from global clinical registration studies in 1678 participants

  • Mitchell F. Brin, MD

      Affiliations

    • Allergan, Irvine, California
    • University of California, Irvine, California
    • Corresponding Author InformationReprint requests: Mitchell F. Brin, MD, Allergan, 2525 Dupont Dr, T1-1B, Irvine, CA 92623-9534.
    • ,
  • Terry I. Boodhoo, MS

      Affiliations

    • Allergan, Irvine, California
    • ,
  • Janice M. Pogoda, PhD

      Affiliations

    • University of Southern California, Los Angeles, California
    • ,
  • Lynn M. James, MPH

      Affiliations

    • Allergan, Irvine, California
    • ,
  • George Demos, MD

      Affiliations

    • Allergan, Irvine, California
    • ,
  • Yasunori Terashima, MD, PhD

      Affiliations

    • GlaxoSmithKline K.K., Shibuya-ku, Tokyo
    • ,
  • Juanhong Gu, MS

      Affiliations

    • GlaxoSmithKline China Investment Co Ltd, Shanghai, China
    • ,
  • Nina Eadie, MBA

      Affiliations

    • independent contractor, Corvallis, Montana
    • ,
  • Beta L. Bowen, MS

      Affiliations

    • Allergan, Irvine, California

,Accepted 8 June 2009.

References 

  1. American Society for Aesthetic Plastic Surgery. 2007 ASAPS statistics. New York: ASAPS; 2008;
  2. Fagien S, Cox SE, Finn JC, Werschler WP, Kowalski JW. Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study. Dermatol Surg. 2007;33:S2–S9
  3. Stotland MA, Kowalski JW, Ray BB. Patient-reported benefit and satisfaction with botulinum toxin type A treatment of moderate to severe glabellar rhytides: results from a prospective open-label study. Plast Reconstr Surg. 2007;120:1386–1393
  4. Carruthers JA, Lowe NJ, Menter MA, Gibson J, Nordquist M, Mordaunt J, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840–849
  5. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:21S–30S
  6. Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg. 2008;32:724–730
  7. Carruthers A, Carruthers J, Lowe NJ, Menter A, Gibson J, Nordquist M, et al. One-year, randomized, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res. 2004;7:1–20
  8. Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257–262
  9. Kawashima M, Harii K. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol. 2009;48:768–776
  10. International Federation of Pharmaceutical Manufacturers and Associations. MedDRA introductory guide V11.0 (updated March 2008). Chantilly (VA). Available from: URL:http://www.meddramsso.com. Accessed September 22, 2008.
  11. Horowitz BZ. Botulinum toxin. Crit Care Clin. 2005;21:825–839viii
  12. Sobel J. Botulism. Clin Infect Dis. 2005;41:1167–1173
  13. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's principles of internal medicine. 16th ed. New York (NY): Mc-Graw Hill Companies; 2005;p. 1157, 1373, 1931
  14. National Cancer Institute (Division of Cancer Treatment and Diagnosis), National Institutes of Health, Department of Health and Human Services. Cancer therapy evaluation program, common terminology criteria for adverse events, Version 3.0. Available from: URL:http://ctep.cancer.gov. Accessed September 22, 2008.
  15. Mozzicato P. Standardized MedDRA queries: their role in signal detection. Drug Saf. 2007;30:617–619
  16. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371
  17. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–1375
  18. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–129
  19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558
  20. SAS Institute, Inc. SAS/Stat user's guide. Cary (NC): SAS Institute Inc; 2003;
  21. Breslow NE, Day NE. Classical methods of analysis of grouped data. Statistical methods in cancer research. Vol I. The analysis of case-control studies (IARC Scientific Publications No. 32). Lyon: International Agency for Research on Cancer; 1980;p. 122-59
  22. Tugnoli V, Capone JG, Eleopra R, Quatrale R, Sensi M, Gastaldo E, et al. Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain. 2007;130:76–83
  23. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Rendt-Nielsen L. Subcutaneous botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain. 2009;141:60–69
  24. Jeong S, Lemke BN, Dortzbach RK, Park YG, Kang HK. The Asian upper eyelid: an anatomical study with comparison to the Caucasian eyelid. Arch Ophthalmol. 1999;117:907–912
  25. McCurdy JA, Lam SM. Asian blepharoplasty. Cosmetic surgery of the Asian face. 2nd ed.. New York: Thieme; 2005;pp. 8-14
  26. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353–1360
  27. Defazio G, Abbruzzese G, Girlanda P, Vacca L, Currà A, De Salvia R, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol. 2002;59:418–420
  28. Smith KC, Alam M. Botulinum toxin for pain relief and treatment of headache. In:  Carruthers A,  Carruthers J editor. Botulinum toxin. 2nd ed. Philadelphia: Saunders Elsevier; 2008;p. 93–103
  29. Kaneko Y, Motohashi Y, Nakamura H, Endo T, Eboshida A. Increasing prevalence of Japanese cedar pollinosis: a meta-regression analysis. Int Arch Allergy Immunol. 2005;136:365–371
  30. Jankovic J, Esquenazi A, Fehlings D, Freitag F, Lang AM, Naumann M. Evidence-based review of patient-reported outcomes with botulinum toxin type A. Clin Neuropharmacol. 2004;27:234–244
  31. Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil. 2006;87:786–792
  32. Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53:407–415
  33. Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord. 2002;17:1288–1293
  34. Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord. 2005;20:592–597
  35. Guirguis-Blake J, Calonge N, Miller T, Siu A, Teutsch S, Whitlock E. Current processes of the US Preventive Services Task Force: refining evidence-based recommendation development. Ann Intern Med. 2007;147:117–122
  36. Food and Drug Administration. Code of Federal Regulations, Title 21, Vol 5. Rockville (MD): Government Printing Office; 2008;
  37. Chapman MA, Barron R, Tanis DC, Gill CE, Charles PD. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia. Clin Ther. 2007;29:1325–1337
  38. Wenzel R, Jones D, Borrego JA. Comparing two botulinum toxin type A formulations using manufacturers' product summaries. J Clin Pharm Ther. 2007;32:387–402
  39. Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, et al. Botulinum toxin treatment of spasmodic torticollis. J R Soc Med. 1992;85:524–529
  40. Brin MF, Blitzer A. Botulinum toxin–dangerous terminology errors. [letter] J R Soc Med. 1993;86:494
  41. Marsden CD. Botulinum toxin–dangerous terminology errors. [reply] J R Soc Med. 1993;86:494
  42. Harper L. Botulinum toxin A–when is a unit not a unit?. J Urol. 2009;181:414–415

 The writing of the manuscript and associated statistical analyses were funded by Allergan. All studies reported herein were funded by the sponsoring pharmaceutical companies: Allergan, GlaxoSmithKline Japan, and GlaxoSmithKline China.

 Disclosure: Dr Brin, Mr Boodhoo, Ms James, Dr Demos, Dr Terashima, Ms Gu, and Ms Bowen are employed by the pharmaceutical companies and receive direct salary compensation. Dr Brin, Ms Eadie, Ms Bowen, Mr Boodhoo, Dr Demos, and Ms James also hold an equity interest in the companies in the form of stock, stock options, or both. Dr Pogoda and Ms Eadie have consulting contracts with Allergan. None of the authors have any commercial associations with any company that makes a competing product. No ghost writers or other third parties were involved in the preparation of the manuscript.

PII: S0190-9622(09)00725-7

doi: 10.1016/j.jaad.2009.06.040

Journal of the American Academy of Dermatology
Volume 61, Issue 6 , Pages 961-970.e11 , December 2009

Article Tools

* Image Usage & Resolution